Cure heart failure with synthetic virus via pioneering gene therapy? – Indian Express [Slide Show] Cure heart failure with synthetic virus via pioneering gene therapy? Continue reading
Tag Archives: heart-failure
Heart Failure First UK Gene Therapy Trial – Video
Heart Failure First UK Gene Therapy Trial By: challa794 Continue reading
Gene therapy for heart failure
Doctors at the Royal Brompton Hospital in London will treat 200 patients next month as part of the first ever gene therapy trial for heart failure, which is taking place in 50 centres around the world. A separate trial, which will test the same therapy in 24 patients who have been fitted with mechanical heart pumps, is expected to begin later this year. Prof Sian Harding of Imperial College London, who developed the treatment, said: “It’s been a painstaking, 20-year process to find the right gene and make a treatment that works, but we’re thrilled to be working with cardiologists to set up human trials that could help people living with heart failure.” Prof Peter Weissberg, Medical Director of the British Heart Foundation, which is co-funding the research, said: “While drugs can offer some relief, there is currently no way of restoring function to the heart for those suffering with heart failure. Continue reading
BG Medicine Welcomes CE Mark for Galectin-3 Test
WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. Continue reading
BG Medicine publishes 2 studies supporting repeat Galectin-3 testing
BG Medicine announced the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart failure. The studies, which together involved more than 3,300 subjects, demonstrate that periodic evaluation of galectin-3 levels can help clinicians identify those at greater risk of unplanned hospital admission and cardiovascular morbidity and mortality. Continue reading
BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients
WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart failure Continue reading
BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test
WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3(R) blood test has obtained a CE Mark, an important step in the company’s commercial strategy Continue reading
Stem cells achieve sustained heart function improvement in heart attack patients – Video
Stem cells achieve sustained heart function improvement in heart attack patients From Louisville – Stem cell therapy has been shown to sustain heart function improvement in heart attack patients in a phase 1 clinical presented at the AHA's Scientific Sessions. The trial, known as SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, randomized 33 patients diagnosed with heart failure after suffering a heart attack to either cardiac stem cells or no stem cells. Researchers found that patients who received the stem cells had great improvement in their heart function, and that this improvement was sustained 2 years following infusion. Continue reading
BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 20, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. Continue reading
Stem Cells And Myocardial Regeneration – Video
Stem Cells And Myocardial Regeneration ll4.me Stem Cells And Myocardial Regeneration “Stem Cells and Myocardial Regeneration- – Table of Contents- – 1. The Challenge for Stem Cell Therapy: Overview of the Problem: Heart Attack and Heart Failure- Marc S. Penn, MD, PhD Eric J Continue reading
First Patient Treated in Cytori’s U.S. Cell Therapy Heart Failure Trial
SAN DIEGO & MINNEAPOLIS–(BUSINESS WIRE)– Cytori Therapeutics (CYTX) announced the initiation of the FDA approved ATHENA clinical trial to investigate Cytoris cell therapy in patients who suffer from a severe form of refractory (untreatable) heart failure due to chronic myocardial ischemia. Cytoris cell therapy is based on a patients own adipose-derived stem and regenerative cells (ADRCs) processed by the Companys proprietary Celution System technology, making this the first FDA approved trial in the U.S. Continue reading
BG Medicine, Inc. to Present at Robert W. Baird 2012 Health Care Conference
WALTHAM, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc Continue reading
BG Medicine, Inc. Announces Publication of Important Galectin-3 Study Designed to Identify Adults in General …
WALTHAM, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the study, “Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community,” was published online in the current issue of the Journal of the American College of Cardiology1 (JACC). Continue reading
BG Medicine, Inc. Announces 510(k) Filing for the ARCHITECT Galectin-3 Assay on the Abbott ARCHITECT Automated Platform
WALTHAM, Mass, July 20, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced the filing of a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance for the ARCHITECT Galectin-3 assay, which is used with Abbott’s fully automated ARCHITECT immunochemistry instrument platform Continue reading
BG Medicine, Inc. to Present at the JMP Securities Healthcare Conference
WALTHAM, Mass., July 9, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it will present at the upcoming JMP Securities Healthcare Conference on Friday, July 13, 2012 at 11:30 a.m. Eastern Time. Continue reading
New finding 'may lead to genetic test that predicts heart failure beforehand'
Washington, June 2 (ANI): The serendipitous chain of events that took place in a new study could lead to a genetic test that can help predict heart failure in certain people before it happens. Continue reading
BG Medicine, Inc. Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3(TM) Indication
WALTHAM, Mass., May 15, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD – News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S Continue reading
Stem Cell Study Shows Promising Results Against Heart Failure
By Denise Mann HealthDay Reporter THURSDAY, May 10 (HealthDay News) — A new treatment that involves spinning bone marrow stem cells to enhance their healing potential may help people with advanced heart failure feel and function better, a small study suggests. Researchers developed the treatment by culturing a patient’s own bone marrow for 12 days. This process helped increase the amount of immune cells and stem cells that can differentiate into several different cell types, including heart cells. Continue reading
BG Medicine Announces First Quarter 2012 Financial Results Release Date and Conference Call Information
WALTHAM, Mass., May 9, 2012 (GLOBE NEWSWIRE) — BG Medicine Inc. (Nasdaq:BGMD – News) today announced that its financial results for the first quarter of fiscal year 2012 will be released before market open on Tuesday, May 15, 2012, followed the same day by a conference call and live webcast scheduled for 8:00am ET Continue reading